Grifols, S.A. (GRFS) vs Sanofi (SNY)
- Grifols, S.A. GRFS 8.43 −0.35%
- Sanofi SNY 47.04 +0.28%
Grifols, S.A. and Sanofi are both Drug Manufacturers General companies. Sanofi is the larger, with a market value of $111.8B against $2.2B — 51.3× the size. Grifols, S.A. trades at the lower P/E: 18.2× against 23.3×. Sanofi grew revenue faster over the last twelve months: 26.3% against 10.9%. Sanofi has the higher net margin (8.27% vs 6.02%) and the higher return on invested capital (7.05% vs 4.76%). Both pay a dividend; Sanofi yields more (5.15% vs 1.12%). Across the 23 metrics below, Sanofi leads on 12 and Grifols, S.A. on 11.
Valuation
Profitability
| Metric | GRFS | SNY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 37.55% | 73.44% | 73.01% |
| Operating margin | 16.69% | 18.73% | 18.34% |
| Net margin | 6.02% | 8.27% | 7.31% |
| Free cash flow margin | 8.51% | 40.26% | 18.56% |
| Return on equity | 5.80% | 0.00% | 5.80% |
| Return on assets | 2.28% | 3.24% | 2.28% |
| Return on invested capital | 4.76% | 7.05% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack